Exicure Overview
- Year Founded
-
2011

- Status
-
Public
- Employees
-
6

- Stock Symbol
-
XCUR

- Investments
-
1
- Share Price
-
$11.50
- (As of Thursday Closing)
Exicure General Information
Description
Exicure Inc is a biotechnology company that develops nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss. It operates in a single segment, which is the discovery, research, and development of treatments based on its SNA (Spherical Nucleic Acid) technology.
Contact Information
Website
www.exicuretx.comCorporate Office
- 2430 North Halsted Street
- Chicago, IL 60614
- United States
Corporate Office
- 2430 North Halsted Street
- Chicago, IL 60614
- United States
Exicure Timeline
Exicure Stock Performance
As of 06-Feb-2025, Exicure’s stock price is $11.50. Its current market cap is $34.9M with 2.61M shares.
(As of Thursday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$11.50 | $10.22 | $1.44 - $36.00 | $34.9M | 2.61M | 764K | -$2.02 |
Exicure Financials Summary
As of 30-Sep-2024, Exicure has a trailing 12-month revenue of $500K.
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
---|---|---|---|---|
EV | 14,325 | 9,683 | (2,485) | (15,608) |
Revenue | 500 | 0 | 28,826 | (483) |
EBITDA | (3,183) | (15,571) | 63 | (60,773) |
Net Income | (4,007) | (16,914) | (2,582) | (64,102) |
Total Assets | 10,631 | 11,580 | 23,328 | 64,868 |
Total Debt | 6,128 | 6,665 | 7,306 | 14,736 |
Exicure Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Exicure Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
---|
Exicure Comparisons
Industry
Financing
Details
Exicure Competitors (93)
One of Exicure’s 93 competitors is Ayala Pharmaceuticals, a Corporation company based in Wilmington, DE.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Ayala Pharmaceuticals | Corporation | Wilmington, DE | ||||
CRISPR Therapeutics | Formerly VC-backed | Zug, Switzerland | ||||
ImmunityBio | Formerly VC-backed | San Diego, CA | ||||
Dynavax Technologies | Formerly VC-backed | Emeryville, CA | ||||
PeproTech | Corporate Backed or Acquired | Cranbury, NJ |
Exicure Patents
Exicure Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20230330129-A1 | Tumor necrosis factor receptor superfamily (tnfrsf) agonists, spherical nucleic acid (sna) tlr9 agonists and checkpoint inhibitors for antitumor therapy | Inactive | 11-Aug-2020 | ||
EP-4192477-A1 | Treatment of skin diseases and disorders using inhibitors of kallikrein-related peptidases (klk) | Inactive | 07-Aug-2020 | ||
US-20220348917-A1 | Liposomal spherical nucleic acid (sna) constructs for splice modulation | Inactive | 04-Sep-2019 | ||
US-20220362398-A1 | Administration of spherical nucleic acids for ophthalmological uses | Inactive | 26-Apr-2019 | ||
EP-3923957-A4 | Combined spherical nucleic acid and checkpoint inhibitor for antitumor therapy | Inactive | 12-Feb-2019 | A61P35/00 |
Exicure Signals
Exicure Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Exicure Acquisitions (1)
Exicure’s most recent deal was a Merger/Acquisition with Max-1 Acquisition. The deal was made on 27-Sep-2017.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
Max-1 Acquisition | 27-Sep-2017 | Merger/Acquisition | Special Purpose Acquisition Company (SPAC) |
Exicure ESG
Risk Overview
Risk Rating
Updated November, 27, 2020
31.98 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,042
Rank
Percentile

Pharmaceuticals
Industry
of 947
Rank
Percentile

Biotechnology
Subindustry
of 427
Rank
Percentile

Exicure FAQs
-
When was Exicure founded?
Exicure was founded in 2011.
-
Where is Exicure headquartered?
Exicure is headquartered in Chicago, IL.
-
What is the size of Exicure?
Exicure has 6 total employees.
-
What industry is Exicure in?
Exicure’s primary industry is Drug Discovery.
-
Is Exicure a private or public company?
Exicure is a Public company.
-
What is Exicure’s stock symbol?
The ticker symbol for Exicure is XCUR.
-
What is the current stock price of Exicure?
As of 06-Feb-2025 the stock price of Exicure is $11.50.
-
What is the current market cap of Exicure?
The current market capitalization of Exicure is $34.9M.
-
What is Exicure’s current revenue?
The trailing twelve month revenue for Exicure is $500K.
-
Who are Exicure’s competitors?
Ayala Pharmaceuticals, CRISPR Therapeutics, ImmunityBio, Dynavax Technologies, and PeproTech are some of the 93 competitors of Exicure.
-
What is Exicure’s annual earnings per share (EPS)?
Exicure’s EPS for 12 months was -$2.02.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »